(Q38661777)

English

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 September 2017

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update (English)

1 reference

Europe PubMed Central

5 September 2017

1 reference

based on heuristic

inferred from title

psoriatic arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

14

1 reference

Europe PubMed Central

5 September 2017

0 references

Dennis McGonagle

24

object named as

D McGonagle

0 references

Philip Helliwell

18

object named as

P Helliwell

0 references

Helena Marzo-Ortega

23

object named as

H Marzo-Ortega

0 references

object named as

L Gossec

1

0 references

object named as

S Ramiro

3

0 references

object named as

R Lories

20

0 references

object named as

K Pavelka

27

0 references

19

object named as

T K Kvien

1 reference

Europe PubMed Central

5 September 2017

Gerd-Rüdiger Burmester

13

object named as

G Burmester

1 reference

Europe PubMed Central

5 September 2017

author name string

J S Smolen

2

1 reference

Europe PubMed Central

5 September 2017

M de Wit

4

1 reference

Europe PubMed Central

5 September 2017

M Cutolo

5

1 reference

Europe PubMed Central

5 September 2017

M Dougados

6

1 reference

Europe PubMed Central

5 September 2017

R Landewé

8

1 reference

Europe PubMed Central

5 September 2017

S Oliver

9

1 reference

Europe PubMed Central

5 September 2017

D Aletaha

10

1 reference

Europe PubMed Central

5 September 2017

N Betteridge

11

1 reference

Europe PubMed Central

5 September 2017

J Braun

12

1 reference

Europe PubMed Central

5 September 2017

N Damjanov

15

1 reference

Europe PubMed Central

5 September 2017

O FitzGerald

16

1 reference

Europe PubMed Central

5 September 2017

E Haglund

17

1 reference

Europe PubMed Central

5 September 2017

T Luger

21

1 reference

Europe PubMed Central

5 September 2017

M Maccarone

22

1 reference

Europe PubMed Central

5 September 2017

I B McInnes

25

1 reference

Europe PubMed Central

5 September 2017

I Olivieri

26

1 reference

Europe PubMed Central

5 September 2017

G Schett

28

1 reference

Europe PubMed Central

5 September 2017

J Sieper

29

1 reference

Europe PubMed Central

5 September 2017

F van den Bosch

30

1 reference

Europe PubMed Central

5 September 2017

D J Veale

31

1 reference

Europe PubMed Central

5 September 2017

J Wollenhaupt

32

1 reference

Europe PubMed Central

5 September 2017

A Zink

33

1 reference

Europe PubMed Central

5 September 2017

D van der Heijde

34

1 reference

Europe PubMed Central

5 September 2017

language of work or name

0 references

publication date

7 December 2015

1 reference

Europe PubMed Central

5 September 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

5 September 2017

75

1 reference

Europe PubMed Central

5 September 2017

3

1 reference

Europe PubMed Central

5 September 2017

499-510

1 reference

Europe PubMed Central

5 September 2017

A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Proposal for a new nomenclature of disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Targeting extra-articular manifestations in PsA: a closer look at enthesitis and dactylitis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Current treatment of psoriatic arthritis: update based on a systematic literature review to establish French Society for Rheumatology (SFR) recommendations for managing spondyloarthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Going from evidence to recommendations

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Incorporating considerations of resources use into grading recommendations

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Recognizing and managing comorbidities in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Psoriatic Arthritis Mutilans: Characteristics and Natural Radiographic History.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Outcomes research in psoriasis and psoriatic arthritis using large databases and research networks: a report from the GRAPPA 2013 Annual Meeting.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Predictors for radiological damage in psoriatic arthritis: results from a single centre

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Clinical and radiological damage in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Composite measures in psoriatic arthritis: GRAPPA 2008.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Development of a preliminary composite disease activity index in psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future?

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Dactylitis in psoriatic arthritis: a marker for disease severity?

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

A randomized placebo-controlled trial of methotrexate in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Clinical improvement in psoriasis with specific targeting of interleukin-23.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Interleukin-17 inhibition in psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Comprehensive treatment of dactylitis in psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis (REmoval of treatment for patients in REmission in psoriatic ArThritis (RETREAT (F))

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

GRAPPA treatment recommendations: an update from the GRAPPA 2013 Annual Meeting

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Treatment recommendations for psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2015-208337

21 January 2018

Identifiers

10.1136/ANNRHEUMDIS-2015-208337

1 reference

Europe PubMed Central

5 September 2017

10.1136/ANNRHEUMDIS-2015-208337

0 references

Dimensions Publication ID

0 references

Microsoft Academic ID

0 references

1 reference

Europe PubMed Central

5 September 2017

2-s2.0-84960126976

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38661777&oldid=1772804345"